Role and safety of tirofiban in peri-interventional antiplatelet management for aneurysm treatment

  • Objectives: Subarachnoid hemorrhage (SAH) may critically impair cardiovascular, metabolic, and gastrointestinal function. Previous research has demonstrated compromised drug absorption in this group of patients. This study aimed to examine the impact of SAH on gastrointestinal function and its subsequent effect on the absorption of enterally administered drugs, using esomeprazole as a probe drug. Design: Prospective observational cohort study. Setting: Academic hospital in Germany. Patients: We included 17 patients with high-grade SAH and 17 controls, comparable in age, sex, body weight, and renal function, who underwent elective cranial surgery. Interventions: None. Measurements and main results: Both groups received esomeprazole per standard protocol to prevent acid-associated mucosal damage, either orally or through a nasogastric tube. On day 4, esomeprazole was administered IV to estimate oral bioavailability. Esomeprazole serum concentrations were measured on daysObjectives: Subarachnoid hemorrhage (SAH) may critically impair cardiovascular, metabolic, and gastrointestinal function. Previous research has demonstrated compromised drug absorption in this group of patients. This study aimed to examine the impact of SAH on gastrointestinal function and its subsequent effect on the absorption of enterally administered drugs, using esomeprazole as a probe drug. Design: Prospective observational cohort study. Setting: Academic hospital in Germany. Patients: We included 17 patients with high-grade SAH and 17 controls, comparable in age, sex, body weight, and renal function, who underwent elective cranial surgery. Interventions: None. Measurements and main results: Both groups received esomeprazole per standard protocol to prevent acid-associated mucosal damage, either orally or through a nasogastric tube. On day 4, esomeprazole was administered IV to estimate oral bioavailability. Esomeprazole serum concentrations were measured on days 1, 3, and 4 in both groups and on day 7 in the SAH group. Patients with high-grade SAH exhibited severely impaired drug absorption. Most patients showed no improvement in intestinal drug absorption even a week after hemorrhage. Conclusions: Following SAH, significantly reduced drug absorption may be attributed to decreased intestinal motility and compromised intestinal mucosal function. Clinicians should anticipate the reduced effectiveness of enterally administered medications for at least seven days after high-grade SAH.show moreshow less

Download full text files

Export metadata

Statistics

Number of document requests

Additional Services

Share in Twitter Search Google Scholar
Metadaten
Author:Rana GarayzadeORCiDGND, Ansgar BerlisORCiDGND, Tim Tobias Arndt, Christina WolfertORCiDGND, Björn SommerORCiD, Gernot MüllerORCiDGND, Christoph Johannes MaurerORCiDGND
URN:urn:nbn:de:bvb:384-opus4-1216830
Frontdoor URLhttps://opus.bibliothek.uni-augsburg.de/opus4/121683
ISSN:1869-1439OPAC
ISSN:1869-1447OPAC
Parent Title (English):Clinical Neuroradiology
Publisher:Springer Science and Business Media LLC
Type:Article
Language:English
Year of first Publication:2025
Publishing Institution:Universität Augsburg
Release Date:2025/05/05
Volume:35
Issue:2
First Page:247
Last Page:254
DOI:https://doi.org/10.1007/s00062-024-01480-6
Institutes:Mathematisch-Naturwissenschaftlich-Technische Fakultät
Mathematisch-Naturwissenschaftlich-Technische Fakultät / Institut für Mathematik
Medizinische Fakultät
Mathematisch-Naturwissenschaftlich-Technische Fakultät / Institut für Mathematik / Lehrstuhl für Rechnerorientierte Statistik und Datenanalyse
Medizinische Fakultät / Universitätsklinikum
Medizinische Fakultät / Lehrstuhl für Diagnostische und Interventionelle Neuroradiologie
Medizinische Fakultät / Lehrstuhl für Neurochirurgie
Dewey Decimal Classification:5 Naturwissenschaften und Mathematik / 51 Mathematik / 510 Mathematik
6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit
Licence (German):CC-BY 4.0: Creative Commons: Namensnennung (mit Print on Demand)